Hanmi Pharmaceutical’s growth momentum continued with its operating profit climbing 49.6% in the second quarter. Beijing Hanmi Pharmaceutical, which had taken a severe blow from COVID-19, successfully achieved a turnaround with its sales rising 119.9% year-over-year.
Hanmi Pharmaceutical posted a temporary notice stating that it achieved EUR 0.2 billion in sales, EUR 11.6 million in operating profit, and EUR 0.6 million in net profit in the second quarter and invested EUR 28 million, 13.8% of the sales, in research and development (R&D). The sales, operating profit, and net profit were up 14.7%, 49.6%, and 43.1%, respectively, year-over-year.
The steady increase in the sales of prescription drugs independently developed by Hanmi Pharm and the astounding growth of Beijing Hanmi Pharmaceutical contributed to this accomplishment. Rosuzet (a new combination drug for treatment of hyperlipidemia), one of the best-selling products from Hanmi Pharm, Amozaltan family (a product line of new combination drugs for treatment of hypertension), and Esomezol (therapeutic agent for reflux esophagitis) recorded EUR 19.6 million, EUR 20.6 million, and EUR 8.9 million in sales, respectively. EUR 38.9 million worth of Rosuzet was sold in the first half of the year alone, which was the biggest sales among all domestic drugs. Amozaltan family expected to surpass the EUR 0.73 billion mark in terms of cumulative sales since their release by the end of this year.
Hanmi Pharmaceutical boasts twelve blockbuster drugs that recorded over EUR 7.3 million in sales last year (incl. Rosuzet, Amozaltan, Esomezol, Amozaltan Plus, Amodipin, Hanmitams, Naxozol, Rovelito, Hyalu Mini, Carnitil, RaboneD, and Pidogul).
According to the company, they reached No. 1 in the outside-the-hospital prescription market once again in the first half of 2021, with the prescription sales climbing 13.8% year-over-year. Hanmi Pharmaceutical has ranked No. 1 in the prescription market for three consecutive years and is expected to maintain this spot this year.
Beijing Hanmi Pharmaceutical achieved a turnaround, recording EUR 43.3 million in sales, a 119.9% YOY growth in the second quarter, and record-high sales in the first half since its establishment. Hanmi Science recorded EUR 0.2 billion in sales, EUR 9.97 million in operating profit, and EUR 7.9 million in net profit in the second quarter, based on the consolidated financial statements, with the operating profit and net profit climbing 44.8% and 36.0% year-over-year, respectively.
Source: Digital Times
